{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:19Z","timestamp":1761941959340,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012411","name":"Alborz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vhri.2023.08.001","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T13:35:25Z","timestamp":1696599325000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran"],"prefix":"10.1016","volume":"38","author":[{"given":"Soroush","family":"Fariman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Momeni Nasab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monireh","family":"Afzali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.vhri.2023.08.001_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study","volume":"12","author":"Ou","year":"2022","journal-title":"Front Oncol"},{"issue":"25","key":"10.1016\/j.vhri.2023.08.001_bib3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.vhri.2023.08.001_bib4","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.vhri.2023.08.001_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment\u2014from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.vhri.2023.08.001_bib6","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in Previously Treated Chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.vhri.2023.08.001_bib8","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022","volume":"20","author":"Wierda","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","author":"Shanafelt","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.08.001_bib13","first-page":"1","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib14","doi-asserted-by":"crossref","DOI":"10.17795\/semj35258","article-title":"Newly defined role of pharmacoeconomics in Iran national medicine policy","volume":"17","author":"Cheraghali","year":"2016","journal-title":"Shiraz E Med J"},{"issue":"12","key":"10.1016\/j.vhri.2023.08.001_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib16","article-title":"A\u00a0systematic review of discounting in national health economic evaluation guidelines: healthcare value implications","volume":"12","author":"Abimbola","year":"2023","journal-title":"J\u00a0Comp Eff Res"},{"year":"1996","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","key":"10.1016\/j.vhri.2023.08.001_bib17"},{"issue":"34","key":"10.1016\/j.vhri.2023.08.001_bib18","first-page":"135","article-title":"Estimation of social discount rate for Iran","volume":"9","author":"Abdoli","year":"2009","journal-title":"Econ Res"},{"issue":"121","key":"10.1016\/j.vhri.2023.08.001_bib19","first-page":"2","article-title":"The cost-effectiveness of ibrutinib in treatment of relapsed or refractory chronic lymphocytic leukemia","volume":"2","author":"Sorensen","year":"2016","journal-title":"Heal Econ Outcome Res Open Access"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.08.001_bib20","doi-asserted-by":"crossref","first-page":"10932","DOI":"10.1182\/blood-2022-163702","article-title":"Treatment patterns of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the era of targeted therapy: a real-world United States study","volume":"140","author":"Yang","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib21","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.3390\/curroncol28060408","article-title":"Examining treatment patterns and real-world outcomes in chronic lymphocytic leukemia using administrative data in Ontario","volume":"28","author":"Seung","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib22","first-page":"291","article-title":"Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center","volume":"3","author":"Ranti","year":"2022","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.vhri.2023.08.001_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"Ishak","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib24","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"author":"Latimer","key":"10.1016\/j.vhri.2023.08.001_bib25"},{"key":"10.1016\/j.vhri.2023.08.001_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40273-015-0332-5","article-title":"Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada","volume":"34","author":"Herring","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2023.08.001_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vhri.2023.08.001_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/CMAR.S17470","article-title":"Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia","volume":"3","author":"Molica","year":"2011","journal-title":"Cancer Manag Res"},{"issue":"suppl 5","key":"10.1016\/j.vhri.2023.08.001_bib31","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib32","first-page":"170","article-title":"Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials","volume":"20","author":"Kilpatrick","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2023.08.001_bib33","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncol (Williston Park)"},{"issue":"5","key":"10.1016\/j.vhri.2023.08.001_bib34","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.vhri.2023.08.001_bib35","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11912-022-01261-9","article-title":"Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies","volume":"24","author":"Rivera","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib36","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","article-title":"How to manage atrial fibrillation secondary to ibrutinib","volume":"3","author":"Essa","year":"2021","journal-title":"JACC Cardiooncol"},{"key":"10.1016\/j.vhri.2023.08.001_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vhri.2023.04.004","article-title":"Upfront DPYD genotype-guided treatment for fluoropyrimidine-based chemotherapy in advanced and metastatic colorectal cancer: a cost-effectiveness analysis","volume":"37","author":"Ahmadi Fariman","year":"2023","journal-title":"Value Heal Reg Issues"},{"issue":"5","key":"10.1016\/j.vhri.2023.08.001_bib39","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.vhri.2023.08.001_bib40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974-2018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib41","first-page":"154","article-title":"Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis","volume":"20","author":"Ayati","year":"2021","journal-title":"Curr J Neurol"},{"key":"10.1016\/j.vhri.2023.08.001_bib42","first-page":"1","article-title":"A\u00a0cost-effectiveness analysis of\u00a0linagliptin add-on to insulin treatment forpatients with type 2 diabetes\u00a0mellitus and chronic kidney disease in Iran","author":"Fariman","year":"2023","journal-title":"J\u00a0Diabetes Metab Disord"},{"issue":"6","key":"10.1016\/j.vhri.2023.08.001_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/PPO.0000000000000411","article-title":"Cost-effectiveness of new targeted agents\u00a0in\u00a0the treatment of chronic lymphocytic leukemia","volume":"25","author":"Harkins","year":"2019","journal-title":"Cancer J"},{"issue":"12","key":"10.1016\/j.vhri.2023.08.001_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"15","key":"10.1016\/j.vhri.2023.08.001_bib45","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","article-title":"Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p","volume":"2","author":"Barnes","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1470-2045(17)30062-1","article-title":"NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation","volume":"18","author":"Mikudina","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib47","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.clml.2017.12.005","article-title":"Cost-effectiveness of ibrutinib compared with obinutuzumab with chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom","volume":"18","author":"Sinha","year":"2018","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"10.1016\/j.vhri.2023.08.001_bib48","first-page":"A108","article-title":"Cost-effectiveness of ibrutinib as frontline treatment for adult patients with chronic lymphocytic leukemia in Belgium","volume":"20","author":"Smet","year":"2017","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.vhri.2023.08.001_bib49","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2165\/00019053-200624110-00007","article-title":"\u201cLost in translation\u201d: accounting for between-country differences in the analysis of multinational cost-effectiveness data","volume":"24","author":"Manca","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vhri.2023.08.001_bib50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12288-018-1011-4","article-title":"Reduced dose ibrutinib due to financial toxicity in CLL","volume":"35","author":"Lad","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"10","key":"10.1016\/j.vhri.2023.08.001_bib52","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.vhri.2023.08.001_bib53","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2023.08.001_bib54","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1182\/blood-2022-155903","article-title":"Real-world treatment patterns and outcomes after ibrutinib discontinuation among elderly medicare beneficiaries with chronic lymphocytic leukemia: an observational study","volume":"140","author":"Huntington","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"5","key":"10.1016\/j.vhri.2023.08.001_bib56","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.vhri.2023.08.001_bib57","first-page":"55","article-title":"Outcomes of reduced frequency dosing of ibrutinib in chronic lymphocytic leukemia patients following complete or partial remission: a pilot study","volume":"9","author":"Alexander","year":"2020","journal-title":"J\u00a0Hematol"},{"issue":"2","key":"10.1016\/j.vhri.2023.08.001_bib58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.vhri.2023.08.001_bib59","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.vhri.2023.08.001_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40199-019-00259-2","article-title":"Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration","volume":"27","author":"Yousefi","year":"2019","journal-title":"Daru"},{"issue":"16","key":"10.1016\/j.vhri.2023.08.001_bib61","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992300078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992300078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:44Z","timestamp":1761941684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992300078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":61,"alternative-id":["S221210992300078X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2023.08.001","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2023.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}